These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26073221)

  • 1. [Differential characteristics of type 2 diabetes in the elderly. Role of dipeptidyl peptidase 4 inhibitors].
    Formiga F; Gómez-Huelgas R; Rodríguez Mañas L
    Rev Esp Geriatr Gerontol; 2016; 51(1):44-51. PubMed ID: 26073221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J; Pegelow K; Bramlage P
    Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
    Wu D; Li L; Liu C
    Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
    Scheen AJ; Charpentier G; Ostgren CJ; Hellqvist A; Gause-Nilsson I
    Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.
    Del Prato S; Taskinen MR; Owens DR; von Eynatten M; Emser A; Gong Y; Chiavetta S; Patel S; Woerle HJ
    J Diabetes Complications; 2013; 27(3):274-9. PubMed ID: 23403068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
    Schweizer A; Dejager S; Bosi E
    Diabetes Obes Metab; 2009 Aug; 11(8):804-12. PubMed ID: 19476473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus.
    Ji L; Han P; Wang X; Liu J; Zheng S; Jou YM; O'Neill EA; Golm GT; Engel SS; Kaufman KD; Shankar RR
    J Diabetes Investig; 2016 Sep; 7(5):727-36. PubMed ID: 27181998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New combination treatments in the management of diabetes: focus on sitagliptin-metformin.
    Green J; Feinglos M
    Vasc Health Risk Manag; 2008; 4(4):743-51. PubMed ID: 19065992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care-based cohort study, with economic assessment of patient outcomes.
    Gordon J; McEwan P; Evans M; Puelles J; Sinclair A
    Diabetes Obes Metab; 2017 May; 19(5):644-653. PubMed ID: 28026911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Type 2 diabetes: interview with Prof. Stephan Matthaei. Reaching HbA1c target value while preventing hypoglycemia].
    Matthaei S
    MMW Fortschr Med; 2009 Oct; 151(42):54. PubMed ID: 19938786
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
    Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.
    McIntosh B; Cameron C; Singh SR; Yu C; Ahuja T; Welton NJ; Dahl M
    Open Med; 2011; 5(1):e35-48. PubMed ID: 22046219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.
    Fonseca V; Staels B; Morgan JD; Shentu Y; Golm GT; Johnson-Levonas AO; Kaufman KD; Goldstein BJ; Steinberg H
    J Diabetes Complications; 2013; 27(2):177-83. PubMed ID: 23116881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?
    Paolisso G; Monami M; Marfella R; Rizzo MR; Mannucci E
    Adv Ther; 2012 Mar; 29(3):218-33. PubMed ID: 22411425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension.
    Hong SM; Park CY; Hwang DM; Han KA; Lee CB; Chung CH; Yoon KH; Mok JO; Park KS; Park SW
    Diabetes Obes Metab; 2017 May; 19(5):654-663. PubMed ID: 28058750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saxagliptin + metformin. Mostly disadvantages.
    Prescrire Int; 2013 Feb; 22(135):40. PubMed ID: 23444500
    [No Abstract]   [Full Text] [Related]  

  • 17. Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.
    Ross SA; Caballero AE; Del Prato S; Gallwitz B; Lewis-D'Agostino D; Bailes Z; Thiemann S; Patel S; Woerle HJ; von Eynatten M
    Postgrad Med; 2016 Nov; 128(8):747-754. PubMed ID: 27684308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
    Kang YM; Jung CH; Lee SH; Kim SW; Song KH; Kim SG; Kim JH; Cho YM; Park TS; Ku BJ; Koh G; Kim DM; Lee BW; Park JY
    Diabetes Metab J; 2019 Aug; 43(4):432-446. PubMed ID: 31237133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide.
    Seck TL; Engel SS; Williams-Herman DE; Sisk CM; Golm GT; Wang H; Kaufman KD; Goldstein BJ
    Diabetes Res Clin Pract; 2011 Jul; 93(1):e15-7. PubMed ID: 21477878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
    Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
    Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.